We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Liquid Biopsy Assay Predicts if Esophageal Cancer Patients Will Respond to Treatment

By LabMedica International staff writers
Posted on 17 Jun 2022
Print article
Image: A liquid biopsy can determine if a patient with esophageal cancer will respond to certain treatments (Photo courtesy of Pexels)
Image: A liquid biopsy can determine if a patient with esophageal cancer will respond to certain treatments (Photo courtesy of Pexels)

Biomarkers are like the X on a treasure map, but instead of indicating the location of unearthed riches, they indicate an individual’s health status. Common biomarkers include certain RNA or protein molecules present in tissues and body fluids that can show doctors that a patient has a specific disease or may respond well to a particular treatment plan. Liquid biopsies are appealing as a non-invasive method for measuring biomarker levels in a body fluid. A team of researchers has now designed such a method for predicting patient outcomes following treatment for esophageal squamous cell carcinoma (ESCC), an aggressive and deadly disease.

Surgery is the typical treatment method for ESCC, but recent research has shown that adding neoadjuvant therapy (NAT) can improve patient survival rates. NAT involves shrinking a tumor using approaches such as chemotherapy or radiation prior to surgery. However, not all patients are responsive to NAT. Unnecessarily performing it can take time for these patients and lead to worse outcomes. Therefore, the team of researchers from Tokyo Medical and Dental University (TMDU, Tokyo, Japan) aimed to identify biomarkers and characteristics that could preemptively indicate an ESCC patient’s response to NAT.

To do this, the team obtained 128 ESCC tissue samples and 58 matched serum samples from two clinical institutions. The serum was obtained prior to any treatment. NAT for these patients involved chemotherapy with 5-fluorouracil and cisplatin, followed by surgery 3 to 5 weeks later. Pathologists then analyzed the surgical specimens for residual tumor cells, which helped them categorize these ESCC patients as completely, partially, or non-responsive to NAT.

After the researchers analyzed their data, they concluded that their panel of mRNAs and microRNAs had significant predictive potential. Interestingly, combining the panel with tumor size data further increased the predictive power. mRNA/microRNA signature was the most effective clinical characteristic amongst various combinations. It worked in both early- and advanced-stage ESCC patients. Overall, the liquid biopsy developed by the researchers may serve as a non-invasive method for predicting ESCC patient response to NAT. This can lead to precision medicine approaches that will significantly improve the prognosis of many patients who have this disease.

“Molecular biomarkers can be extremely useful when making clinical decisions,” said lead author of the study Keisuke Okuno. “We also wanted to translate these biomarkers into an easy-to-use liquid biopsy.

“We then examined these patient samples for expression levels of molecules that included three mRNAs and four microRNAs,” added Ajay Goel, senior author of the article. “In previous studies, this panel of mRNAs and microRNAs was found to effectively predict ESCC patient response to NAT.”

“We then utilized the pre-treatment serum samples to translate this signature into a liquid biopsy assay, and our approach still maintained its strong ability to predict response to NAT,” explained Okuno.

Related Links:
TMDU 

Platinum Supplier
Xylazine Immunoassay Test
Xylazine ELISA
Gold Supplier
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Chikungunya & Dengue Virus Test
cobas CHIKV/DENV

Print article

Channels

Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Hematology

view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more

Immunology

view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more

Microbiology

view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more

Pathology

view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more

Technology

view channel
Image: Made-to-order diagnostic tests may soon be on the horizon (Photo courtesy of McGill University)

Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible

Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read more

Industry

view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.